DiMarco, CS, Speroff, L, Glass, RH, Kase, NG (eds.). Clinical gynecologic endocrinology and infertility. 6th edition. Baltimore, MD: Lippincott, Williams & Wilkins, 1999.Google Scholar

Moghissi, KS. Gonadotropin releasing hormones: Clinical applications in gynecology. J Reprod Med. 1990;35(12):1097–1107.Google ScholarPubMed

Moghissi, KS. Vulnerable targets for contraception in the female. Global Libra Women’s Med FIGO. 2009.Google Scholar

Skorupskaite, K, George, JT, Anderson, RA. The kisspeptin–GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485–500.CrossRefGoogle ScholarPubMed

Adashi, EY. Intraovarian peptides: Stimulators and inhibitors of follicular growth and differentiation. Endocrinol Metab Clin of North Am. 1992;21(1):1–17.CrossRefGoogle ScholarPubMed

Chengalvala, MV, Meade, EH, Cottom, JE et al. Regulation of female fertility and identification of future contraceptive targets. Curr Pharm Des. 2006;12(30):3915–28.CrossRefGoogle ScholarPubMed

ES H. Transport of spermatozoa in the female reproductive tract. Am J Obstet Gynecol. 1973;115(5):703–17.Google Scholar

Lyons, RA, Saridogan, E, Djahanbakhch, O. The reproductive significance of human Fallopian tube cilia. Hum Reprod Update. 2006;12(4):363–72.CrossRefGoogle ScholarPubMed

Deligdisch, L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13(3):285–94.CrossRefGoogle ScholarPubMed

Salamonsen, LA. Tissue injury and repair in the female human reproductive tract. Reproduction. 2003;125(3):301–11.CrossRefGoogle ScholarPubMed

Hickey, M, Salamonsen, LA. Endometrial structural and inflammatory changes with exogenous progestogens. Trends in Endocrinology and Metabolism. 2008;19(5):167–74.CrossRefGoogle ScholarPubMed

Han, L, Taub, R, Jensen, JT. Cervical mucus and contraception: What we know and what we don’t. Contraception. 2017;96(5):310–21.CrossRefGoogle ScholarPubMed

Ortiz, ME, Croxatto, HB. Copper-T intrauterine device and levonorgestrel intrauterine system: Biological bases of their mechanism of action. Contraception. 2007;75(6 Suppl):S16–30.CrossRefGoogle ScholarPubMed

Erkkola, R. Recent advances in hormonal contraception. Curr Opin Obstet Gynecol. 2007;19(6):547–53.CrossRefGoogle ScholarPubMed

Baird, DT, Collins, J, Cooke, I et al. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16(7)1527–35.Google Scholar

Burkman, RT. Transdermal hormonal contraception: Benefits and risks. Am J Obstet Gynecol. 2007;197(2):134.e1–6.CrossRefGoogle ScholarPubMed

Brache, V, Faundes, A. Contraceptive vaginal rings: A review. Contraception. 2010;82(5):418–27.CrossRefGoogle ScholarPubMed

Sitruk-Ware, R, Nath, A. The use of newer progestins for contraception. Contraception. 2010;82(5):410–17.CrossRefGoogle ScholarPubMed

Jacobstein, R, Polis, CB. Progestin-only contraception: Injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):795–806.CrossRefGoogle ScholarPubMed

Apter, D, Gemzell-Danielsson, K, Hauck, B, Rosen, K, Zurth, C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: Pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6):1656–62.CrossRefGoogle ScholarPubMed

Wagenfeld, A, Saunders, PTK, Whitaker, L, Critchley, HOD. Selective progesterone receptor modulators (SPRMs): Progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20(9):1045–54.CrossRefGoogle ScholarPubMed

Jadav, SP, Parmar, DM. Ulipristal acetate: A progesterone receptor modulator for emergency contraception. J Pharmacol aPharmacother. 2012;3(2):109–11.Google ScholarPubMed

Araû, VR, Gastal, MO, Figueiredo, JR, Gastal, EL. In vitro culture of bovine prenatal follicles: A review. Reprod. Biol. Endocrinol. 2014;12:78. https://doi.org/10.1186/1477-7827-12-78.Google Scholar

Andersen, AN, Ernst, E, 2011. Gynækologisk Endokrinologi. In Ottesen, B, Mogensen, O, Forman, A (eds.), Gynækologi. 4th edition. Copenhagen: Munksgaard Danmark, 2011.Google Scholar

International Conference on Population and Development (ICPD). Programme of Action of the International Conference on Population and Development, Cairo, Egypt, 5–13 September 1994, ch. VII, para. 7.2, 7.12, U.N. Doc. A/CONF.171/13/ Rev.1 (1995).Google Scholar

Center for Reproductive Rights. The right to contraceptive information and services for women and adolescents. New York: Center for Reproductive Rights, 2010.Google Scholar

Kaplan, DM, Tarvydas, VM, Gladding, ST. 20/20: A vision for the future of counselling. Journal of Counseling & Development. 2014;92:366–72.CrossRefGoogle Scholar

Lambert, M, Barley, DE. Research summary of the therapeutic relationship and psychotherapy outcome. Psychotherapy Theory Research & Practice. 2001;38(4):357–61.CrossRefGoogle Scholar

Shelton, JD, Jacobstein, RA, Angle, MA. Medical barriers to access to family planning. Lancet. 1992;340(8831):1334–5. https://doi.org/10.1016/0140-6736(92)92505-A. Pmid: 1360046.CrossRefGoogle ScholarPubMed

Solo, J, Festin, M. Provider bias in family planning services: A review of its meaning and manifestations. Global Health: Science and Practice, September 2019. GHSP-D-19–00130. https://doi.org/10.9745/GHSp-D-19-00130.CrossRefGoogle Scholar

Calhoun, LM, Speizer, IS, Rimal, R et al. Provider imposed restrictions to clients’ access to family planning in urban Uttar Pradesh, India: A mixed methods study. BMC Health Serv Res. 2013;13(1):532. https://doi.org/10.1186/1472-6963-13-532. Pmid:23465015.CrossRefGoogle ScholarPubMed

Dehlendorf, C, Krajewski, C, Borrero, S. Contraceptive counseling: Best practices to ensure quality communication and enable effective contraceptive use. Clinical Obstetrics and Gynecology. 2014;57(4):659–73. https://doi.org/10.1097/GRF.0000000000000059.CrossRefGoogle ScholarPubMed

Gavin, L, Moskosky, S, Carter, M et al. Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs. Morbidity and Mortality Weekly Report: Recommendations and Reports. 2014;63(4):1–54.Google ScholarPubMed

Stanford, JB, Mikolajczyk, RT. Mechanisms of action of intrauterine devices: Update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002;187:1699–1708.CrossRefGoogle ScholarPubMed

Hubacher, D. Intrauterine devices & infection: Review of the literature. Indian J Med Res. 2014;140(Suppl 1):S53–S57.Google ScholarPubMed

Bruce, J. Fundamental elements of the quality of care: A simple framework. Studies in Family Planning. 1990;21(2):61–91. https://doi.org/10.2307/19666691.CrossRefGoogle ScholarPubMed

World Health Organization, Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs, Knowledge for Health Project. Family planning: A global handbook for providers (2018 update). Geneva: World Health Organization, Department of Reproductive Health and Research and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs, Knowledge for Health Project, 2018.Google Scholar

Cavallaro, FL, Benova, L, Owolabi, OO et al. A systematic review of the effectiveness of counselling strategies for modern contraceptive methods: What works and what doesn’t? BMJ Sex Reprod Health. 2019;0:1–16. Published Online First: 11 December 2019. https://doi.org/10.1136/bmjsrh-2019-200377.Google Scholar

Bitzer, J, Abalos, V, Apter, D, Martin, R, Black, A for Global CARE Group. Targeting factors for change: Contraceptive counselling and care of female adolescents. European Journal of Contraception and Reproductive Health Care. 2016;21(6):417–30. https://doi.org/10.1080/13625187.2016.1237629.Google Scholar

Rinehart, W, Rudy, S, Drennan, M. GATHER guide to counseling. Popul Rep J. 1998;48:1–31.Google Scholar

Sitruk-Ware, R, Nath, A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24.CrossRefGoogle ScholarPubMed

Godsland, IF, Crook, D, Simpson, R et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323(20):1375–81.CrossRefGoogle ScholarPubMed

Dragoman, M, Curtis, KM, Gaffield, ME. Combined hormonal contraceptive use among women with known dyslipidemias: A systematic review of critical safety outcomes. Contraception. 2016;94(3):280–7.CrossRefGoogle ScholarPubMed

Speroff, L. Clinical gynecologic endocrinology and infertility. 8th edition. Philadelphia, PA: Lippincott, Williams and Wilkins, 2010.Google Scholar

Petersen, KR, Skouby, SO, Vedel, P, Haaber, AB. Hormonal contraception in women with IDDM: Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care. 1995;18(6):800–6.CrossRefGoogle ScholarPubMed

Trussell, J, Portman, D. The creeping pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? Contraception. 2013;88(5):604–10.CrossRefGoogle ScholarPubMed

European Society for Contraception Teaching and Training tool CHC session. 2019. https://escrheu/education/training-improvement-programme/tt-tool-sessions-eng.Google Scholar

Merki-Feld, GS, Bitzer, J. Contraception in adolescents with anorexia nervosa: Is there evidence for a negative impact of combined hormonal contraceptives on bone mineral density and the course of the disease? Eur J Contracept Reprod Health Care. 2020;25(3):213–20.CrossRefGoogle Scholar

Fernandez, E, La Vecchia, C, Balducci, A et al. Oral contraceptives and colorectal cancer risk: A meta-analysis. Br J Cancer. 2001;84(5):722–7.CrossRefGoogle ScholarPubMed

Iversen, L, Sivasubramaniam, S, Lee, AJ, Fielding, S, Hannaford, PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580e581–580e589.CrossRefGoogle ScholarPubMed

Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. CHC-CVD final report 111022v2. 2011.Google Scholar

Dragoman, MV, Tepper, NK, Fu, R. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–94.CrossRefGoogle ScholarPubMed

VTE risk with CHC. European medical agency. 2013. bit.ly/3DoQFLC.Google Scholar

Dinger, J, Assmann, A, Mohner, S, Minh, TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: Results from a German case-control study. J Fam Plann Reprod Health Care. 2010;36(3):123–9.CrossRefGoogle ScholarPubMed

Van Vlijmen, EF, Wiewel-Verschueren, S, Monster, TB, Meijer, K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2016;14(7):1393–1403.CrossRefGoogle ScholarPubMed

Bezemer, ID, Van der Meer, FJ, Eikenboom, JC, Rosendaal, FR, Doggen, CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6):610–15.CrossRefGoogle ScholarPubMed

Zoller, B, Li, X, Ohlsson, H, Sundquist, J, Sundquist, K. Age-and sex-specific seasonal variation of venous thromboembolism in patients with and without family history: A nationwide family study in Sweden. Thromb Haemost. 2013;110(6):1164–71.Google ScholarPubMed

Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1997;349(9060):1202–9.Google Scholar

Lidegaard, O, Lokkegaard, E, Jensen, A, Skovlund, CW, Keiding, N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257–66.CrossRefGoogle ScholarPubMed

Curtis, KM, Mohllajee, AP, Peterson, HB. Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: A systematic review. Contraception. 2006;73(2):189–94.Google ScholarPubMed

Tzourio, C, Kittner, SJ, Bousser, MG, Alperovitch, A. Migraine and stroke in young women. Cephalalgia. 2000;20(3):190–9.CrossRefGoogle ScholarPubMed

Merki-Feld, GS, Skouby, S, Serfaty, D. European society of contraception statement on contraception in obese women. Eur J Contracept Reprod Health Care. 2015;20(1):19–28.CrossRefGoogle ScholarPubMed

Sacco, S, Merki-Feld, GS, Bitzer, J et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: A consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19(1):76.CrossRefGoogle ScholarPubMed

Merki-Feld, GS, Imthurn, B, Langner, R, Seifert, B, Gantenbein, AR. Positive effects of the progestin desogestrel 75 mug on migraine frequency and use of acute medication are sustained over a treatment period of 180 days. J Headache Pain. 2015;16:522.CrossRefGoogle Scholar

Morch, LS, Skovlund, CW, Hannaford, PC et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–39.CrossRefGoogle ScholarPubMed

Loopik, DL, IntHout, J, Melchers, WJG et al. Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: A population-based study. Eur J Cancer. 2020;124 :102–9.CrossRefGoogle ScholarPubMed

International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby, P, Beral, V et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–21.Google Scholar

Skovlund, CW, Morch, LS, Kessing, LV, Lidegaard, O. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73(11):1154–62.CrossRefGoogle ScholarPubMed

Hani, D, Imthurn, B, Merki-Feld, GS. [Weight gain due to hormonal contraception: Myth or truth?]. Gynakol Geburtshilfliche Rundsch. 2009;49(2):87–93.Google ScholarPubMed

Gallo, MF, Lopez, LM, Grimes, DA et al. Combination contraceptives: Effects on weight. Cochrane Database Syst Rev. 201;1:CD003987.Google Scholar

Trussell, J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.CrossRefGoogle ScholarPubMed

Palacios, S, Colli, E, Regidor, PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98:1549–57.CrossRefGoogle ScholarPubMed

Philips, SJ, Tepper, NK, Kapp, N et al. Progestogen-only contraceptive use among breastfeeding women: A systematic review. Contraception. 2016;94:226–52.CrossRefGoogle Scholar

Tepper, NK, Whiteman, MK, Marchbanks, PA, James, AH, Curtis, KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94:678–800.CrossRefGoogle ScholarPubMed

World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015. bit.ly/3RiJdHy.Google Scholar

Zigler, RE, McNicholas, C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;5:443–50.Google Scholar

Abdel-Aleem, H, d’Arcangues, C, Vogelsong, KM, Gaffield, ML, Gülmezoglu, AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. Cochrane Database Syst Rev. 2013;CD003449.CrossRefGoogle Scholar

Lopez, LM, Ramesh, S, Chen, M et al. Progestin-only contraceptives: Effects on weight. Cochrane Database Syst Rev. 2016;CD008815.CrossRefGoogle Scholar

Mørch, LS, Skovlund, CW, Hannaford, PC et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377:2228–39.CrossRefGoogle ScholarPubMed

Skovlund, CW, Mørch, LS, Kessing, LV, Lidegaard, Ø. Association of hormonal contraceptives with depression. JAMA Psychiatry. 2016;73:1154–62.CrossRefGoogle ScholarPubMed

Benagiano, G, Primiero, FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci. 2003;997:163–73.CrossRefGoogle ScholarPubMed

Archer, DF, Ahrendt, H-J, Drouin, D. Drospirenone-only oral contraceptive: Results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92:439–44.CrossRefGoogle ScholarPubMed

Duijkers, IJ, Heger-Mahn, D, Drouin, D, Skouby, S. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015;20:419–27.CrossRefGoogle Scholar

Sacco, S, Merki-Feld, GS, Aegidius, KL et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: A consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive health (ESCRH). Journal of Headache and Pain. 2018;19:76–96.CrossRefGoogle ScholarPubMed

Brache, V, Cochon, L, Duijkers, IJM et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod. 2015;13:2785–93.Google Scholar

Palomba, S, Falbo, A, Di Cello, A, Materazzo, C, Zullo, F. Nexplanon: The new implant for long-term contraception. A comprehensive descriptive review. Gynecol Endocrinol. 2012;9:710–21.Google Scholar

Lazorwitz, A, Aquilante, CL, Sheeder, J, Guiahi, M, Teal, S. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users. Contraception. 2019;100:37–41.CrossRefGoogle ScholarPubMed

McNicholas, C, Swor, E, Wan, L, Peipert, JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond FDA-approved duration. Am J Obstet Gynecol. 2017;6:586.e1–586.e6.CrossRefGoogle Scholar

Mansour, D, Korver, T, Marintcheva-Petrova, M, Fraser, IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):13–28.CrossRefGoogle ScholarPubMed

Blumenthal, PD, Gemzell-Danielsson, K, Marintcheva-Petrova, M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care. 2008;13(Suppl 1):29–36.CrossRefGoogle ScholarPubMed

Kaunitz, AM, Darney, PD, Ross, D, Wolter, KD, Speroff, L. Subcutaneous DMPA vs. intramuscular DMPA: A 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80:7–17.CrossRefGoogle ScholarPubMed

Said, S, Omar, K, Koetsawang, S et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg. II: The comparison of bleeding patterns. Contraception. 1987;35:591–607.CrossRefGoogle ScholarPubMed

Lange, HLH, Manos, BE, Gothard, MD, Rogers, LK, Bonny, AE. Bone mineral density and weight changes in adolescents randomized to 3 doses of depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2017;30:169–75.CrossRefGoogle ScholarPubMed

Kohn, JE, Simons, HR, Badia, LD et al. Increased 1-year continuation of DMPA among women randomized to self-administration: Results from a randomized controlled trial at Planned Parenthood. Contraception. 2018;97:198–204.CrossRefGoogle ScholarPubMed

Reinecke, I, Hofmann, B, Mesic, E, Drenth, HJ, Garmann, D. An integrated population pharmacokinetic analysis to characterize levonorgestrel pharmacokinetics after different administration routes. J Clin Pharmacol. 2018;58:1639–54.CrossRefGoogle ScholarPubMed

Apter, D, Gemzell-Danielsson, K, Hauck, B, Rosen, K, Zurth, C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: Pooled analyses of phase II and III studies. Fertil Steril. 2014;101:1656–62.e1–4.CrossRefGoogle ScholarPubMed

Goldthwaite, LM, Creinin, MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. Contraception. 2019;100:128–31.CrossRefGoogle ScholarPubMed

Sergison, JE, Maldonado, LY, Gao, X, Hubacher, D. Levonorgestrel intrauterine system associated amenorrhea: A systematic review and metaanalysis. Am J Obstet Gynecol. 2019;220:440–8.e8.CrossRefGoogle ScholarPubMed

Gemzell-Danielsson, K, Schellschmidt, I, Apter, D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97:616–22.e1–3.CrossRefGoogle ScholarPubMed

Kavanaugh, ML, Jerman, J. Contraceptive method use in the United States: Trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97:14–21. https://doi.org/10.1016/j.contraception.2017.10.003.CrossRefGoogle ScholarPubMed

Hassoun, D. [Natural family planning methods and barrier: CNGOF contraception guidelines]. Gynecol Obstet Fertil Senol. 2018;46:873–82. https://doi.org/10.1016/j.gofs.2018.10.002.Google ScholarPubMed

Han, L, Taub, R, Jensen, JT. Cervical mucus and contraception: What we know and what we don’t. Contraception. 2017;96:310–21. https://doi.org/10.1016/j.contraception.2017.07.168.CrossRefGoogle ScholarPubMed

Sung, S, Abramovitz, A. Natural family planning. Bethesda, MD: StatPearls, 2020.Google Scholar

Klaus, H. Natural family planning: A review. Obstet Gynecol Surv. 1982;37:128–50. https://doi.org/10.1097/00006254-198202000-00026.CrossRefGoogle ScholarPubMed

Bradley, SEK, Polis, CB, Bankole, A, Croft, T. Global contraceptive failure rates: Who is most at risk? Stud Fam Plann. 2019;50:3–24. https://doi.org/10.1111/sifp.12085.CrossRefGoogle ScholarPubMed

Polis, CB, Jones, RK. Multiple contraceptive method use and prevalence of fertility awareness based method use in the United States, 2013–2015. Contraception. 2018;98:188–92. https://doi.org/10.1016/j.contraception.2018.04.013.CrossRefGoogle ScholarPubMed

Duane, M, Contreras, A, Jensen, ET, White, A. The performance of fertility awareness–based method apps marketed to avoid pregnancy. J Am Board Fam Med. 2016;29:508–11. https://doi.org/10.3122/jabfm.2016.04.160022.CrossRefGoogle ScholarPubMed

Grimes, DA, Gallo, MF, Grigorieva, V et al. Fertility awareness-based methods for contraception: Systematic review of randomized controlled trials. Contraception. 2005;72:85–90. https://doi.org/10.1016/j.contraception.2005.03.010.CrossRefGoogle ScholarPubMed

Peragallo Urrutia, R, Polis, CB, Jensen, ET et al. Effectiveness of fertility awareness–based methods for pregnancy prevention: A systematic review. Obstet Gynecol. 2018;132:591–604. https://doi.org/10.1097/AOG.0000000000002784.CrossRefGoogle ScholarPubMed

Daunter, B, Counsilman, C. Cervical mucus: Its structure and possible biological functions. Eur J Obstet Gynecol Reprod Biol. 1980;10:141–61. https://doi.org/10.1016/0028-2243(80)90056-8.CrossRefGoogle ScholarPubMed

Su, H-W, Yi, Y-C, Wei, T-Y et al. Detection of ovulation: A review of currently available methods. Bioeng Transl Med. 2017;2:238–46. https://doi.org/10.1002/btm2.10058.CrossRefGoogle ScholarPubMed

Johnson, S, Marriott, L, Zinaman, M. Can apps and calendar methods predict ovulation with accuracy? Curr Med Res Opin. 2018;34:1587–94. https://doi.org/10.1080/03007995.2018.1475348.CrossRefGoogle ScholarPubMed

Nilsson, A, Ahlborg, T, Bernhardsson, S. Use of non-medical contraceptive methods: A survey of women in western Sweden. Eur J Contracept Reprod Health Care. 2018;23:400–6. https://doi.org/10.1080/13625187.2018.1541079.CrossRefGoogle ScholarPubMed

Marston, CA, Church, K. Does the evidence support global promotion of the calendar-based Standard Days Method® of contraception? Contraception. 2016;93:492–7. https://doi.org/10.1016/j.contraception.2016.01.006.CrossRefGoogle ScholarPubMed

Pyper, C. Natural family planning: Low failure rate with symptothermal method. BMJ. 1993;307:1359–60. https://doi.org/10.1136/bmj.307.6915.1359-c.CrossRefGoogle ScholarPubMed

Soler, F, Barranco-Castillo, E. The symptothermal (double check) method: An efficient natural method of family planning. Eur J Contracept Reprod Health Care. 2010;15:379–80, author reply at 381. https://doi.org/10.3109/13625187.2010.505990.CrossRefGoogle ScholarPubMed

Geerling, JH. Natural family planning. Am Fam Physician. 1995;52:1749–56, 1759.Google ScholarPubMed

Bouchard, TP, Genuis, SJ. Personal fertility monitors for contraception. Can Med Assoc J. 2011;183:73–6. https://doi.org/10.1503/cmaj.090195.CrossRefGoogle ScholarPubMed

Bonnar, J, Flynn, A, Freundl, G et al. Personal hormone monitoring for contraception. Br J Fam Plann. 1999;24:128–34.Google ScholarPubMed

Moglia, ML, Nguyen, HV, Chyjek, K et al. Evaluation of smartphone menstrual cycle tracking applications using an adapted APPLICATIONS scoring system. Obstet Gynecol. 2016;127:1153–60. https://doi.org/10.1097/AOG.0000000000001444.CrossRefGoogle ScholarPubMed

Freis, A, Freundl-Schütt, T, Wallwiener, LM et al. Plausibility of menstrual cycle apps claiming to support conception. Front Public Health. 2018;6:98–102. https://doi.org/10.3389/fpubh.2018.00098.CrossRefGoogle ScholarPubMed

Zwingerman, R, Chaikof, M, Jones, C. A critical appraisal of fertility and menstrual tracking apps for the iPhone. J Obstet Gynaecol Can. 2019. https://doi.org/10.1016/j.jogc.2019.09.023.CrossRefGoogle Scholar

Gambier-Ross, K, McLernon, DJ, Morgan, HM. A mixed methods exploratory study of women’s relationships with and uses of fertility tracking apps. Digit Health. 2018;4:2055207618785077. https://doi.org/10.1177/2055207618785077.Google ScholarPubMed

Berglund Scherwitzl, E, Lindén Hirschberg, A, Scherwitzl, R. Identification and prediction of the fertile window using NaturalCycles. Eur J Contracept Reprod Health Care. 2015;20:403–8. https://doi.org/10.3109/13625187.2014.988210.CrossRefGoogle ScholarPubMed

Berglund Scherwitzl, E, Lundberg, O, Kopp Kallner, H et al. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. Contraception. 2017;96:420–5. https://doi.org/10.1016/j.contraception.2017.08.014.CrossRefGoogle ScholarPubMed

Evans, WD, Ulasevich, A, Hatheway, M, Deperthes, B. Systematic review of peer-reviewed literature on global condom promotion programs. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17072262.CrossRefGoogle Scholar

Gossman, W, Shaeffer, AD, McNabb, DM. Condoms. StatPearls, 2020.Google Scholar

Sanders, SA, Yarber, WL, Kaufman, EL et al. Condom use errors and problems: A global view. Sex Health. 2012;9:81–95. https://doi.org/10.1071/SH11095.CrossRefGoogle ScholarPubMed

Raidoo, S, Kaneshiro, B. Contraception counseling for adolescents. Curr Opin Obstet Gynecol. 2017;29:310–15. https://doi.org/10.1097/GCO.0000000000000390.CrossRefGoogle ScholarPubMed

Beksinska, M, Wong, R, Smit, J. Male and female condoms: Their key role in pregnancy and STI/HIV prevention. Best Pract Res Clin Obstet Gynaecol. 2020;66:55–67. https://doi.org/10.1016/j.bpobgyn.2019.12.001.CrossRefGoogle ScholarPubMed

Maksut, JL, Eaton, LA. Female condoms = missed opportunities: Lessons learned from promotion-centered interventions. Women’s Health Issues. 2015;25:366–76. https://doi.org/10.1016/j.whi.2015.03.015.CrossRefGoogle ScholarPubMed

Bounds, W. Female condoms. Eur J Contracept Reprod Health Care. 1997;2:113–16. https://doi.org/10.3109/13625189709167464.CrossRefGoogle ScholarPubMed

Edouard, L. The renaissance of barrier methods. J Fam Plann Reprod Health Care. 2012;38:131–3. https://doi.org/10.1136/jfprhc-2012-100314.CrossRefGoogle ScholarPubMed

Mauck, C, Callahan, M, Weiner, DH, Dominik, R. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm: The FemCap Investigators’ Group. Contraception. 1999;60:71–80. https://doi.org/10.1016/s0010-7824(99)00068-2.CrossRefGoogle ScholarPubMed

Lech, MM. Spermicides 2002: An overview. Eur J Contracept Reprod Health Care. 2002;7:173–7.CrossRefGoogle ScholarPubMed

Dev, R, Kohler, P, Feder, M et al. A systematic review and meta-analysis of postpartum contraceptive use among women in low- and middle-income countries. Reprod Health. 2019;16:154. https://doi.org/10.1186/s12978-019-0824-4.CrossRefGoogle ScholarPubMed

Tredway, DR, Umezaki, CU, Mishell, DR Jr, Settlage, DS. Effect of intrauterine devices on sperm transport in the human being: Preliminary report. Am J Obstet Gynecol. 1975;123(7):734–5.CrossRefGoogle ScholarPubMed

Winner, B, Peipert, JF, Zhao, Q et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.CrossRefGoogle ScholarPubMed

World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015. www.who.int/publications/i/item/9789241549158.Google Scholar

Castellsagué, X, Thompson, WD, Dubrow, R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer. 1993;54(6):911–16.CrossRefGoogle ScholarPubMed

Milsom, I, Andersson, K Jonasson, K, Lindstedt, G, Rybo, G. Contraception: The influence of the Gyne-T 380S IUD on menstrual blood loss and iron status. Contraception. 1995;52(3):175–9.CrossRefGoogle ScholarPubMed

Whiteman, MK, Tyler, CP, Folger, SG, Gaffield, ME, Curtis, KM. When can a woman have an intrauterine device inserted? A systematic review. Contraception. 2013;87(5):666–73.CrossRefGoogle ScholarPubMed

Lopez, LM, Bernholc, A, Hubacher, D, Stuart, G, Van Vliet, HA. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev. 2015;(6):CD003036.Google ScholarPubMed

Gemzell-Danielsson, K, Jensen, JT, Monteiro, I et al. Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: An updated review. Acta Obstet Gynecol Scand. 2019;98(12):1500–13.CrossRefGoogle ScholarPubMed

Sääv, I, Aronsson, A, Marions, L, Stephansson, O, Gemzell-Danielsson, K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial. Hum Reprod. 2007;22(10):2647–52.CrossRefGoogle ScholarPubMed

Mishell, DR Jr, Bell, JH, Good, RG, Moyer, DL. The intrauterine device: A bacteriologic study of the endometrial cavity. Am J Obstet Gynecol. 1966;96 (1):119–26. https://doi.org/10.1016/s0002-9378(16)34650-6.CrossRefGoogle ScholarPubMed

FSRH Guidance. Intrauterine contraception. 2015. bit.ly/3kVvj1Y.Google Scholar

Farley, TM, Rosenberg, MJ, Rowe, PJ, Chen, JH, Meirik, O. Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet. 1992;339(8796):785–8.CrossRefGoogle ScholarPubMed

Hubacher, D, Lara-Ricalde, R, Taylor, DJ, Guerra-Infante, F, Guzmán-Rodríguez, R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345(8):561–7.CrossRefGoogle ScholarPubMed

Brahmi, D, Steenland, MW, Renner, RM, Gaffield, ME, Curtis, KM. Pregnancy outcomes with an IUD in situ: A systematic review. Contraception. 2012;85(2):131–9.CrossRefGoogle ScholarPubMed

Tepper, NK, Steenland, MW, Gaffield, ME, Marchbanks, PA, Curtis, KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: A systematic review. Contraception. 2013;87(5):655–60.CrossRefGoogle ScholarPubMed

Daniels, K, Daugherty, J, Jones, J. Current contraceptive status among women aged 15–44: United States, 2011–2013. NCHS Data Brief. 2014;173:1–8.Google Scholar

March, CM. Female tubal sterilization. In Shoupe, D (ed.), The handbook of contraception. 3rd edition. Cham: Humana, 2020, pp. 193–238.CrossRefGoogle Scholar

Hulka, JF. Methods of female sterilization. In Nichols, DH, Clarke-Pearson, DL (eds.), Gynecologic and obstetric surgery. St. Louis, MO: Mosby, 2000, pp. 626–40.Google Scholar

Beerthuizen, R. State-of-the-art of non-hormonal methods of contraception: V. Female sterilisation. Eur J Contracept Reprod Health Care. 2010;15:124–35.CrossRefGoogle ScholarPubMed

Steele, SJ. The potential for improved abdominal procedures and approaches for tubal occlusion. Int J Gynaecol Obstet. 1995;51:S17–S22.CrossRefGoogle ScholarPubMed

Rodriguez, M, Seuc, A, Sokal, D. Comparative efficacy of postpartum sterilization with the titanium clip versus partial salpingectomy: A randomized controlled trial. BJOG. 2013;120(1):108–12.CrossRefGoogle Scholar

Peterson, HB, Xia, Z, Hughes, JM et al. The risk of pregnancy after tubal sterilization: Findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161–8.CrossRefGoogle ScholarPubMed

Peterson, HB, Xia, Z, Wilcox, LS et al. Pregnancy after tubal sterilization with bipolar electrocoagulation: U.S. Collaborative Review of Sterilization Working Group. Obstet Gynecol. 1999;94:163–7.Google ScholarPubMed

Abbott, J. Transcervical sterilization. Best Pract Res Clin Obstet Gynaecol. 2005;19:743–56.CrossRefGoogle ScholarPubMed

Quiñones, R, Alvarado, A, Ley, E. Hysteroscopic sterilization. Int J Gynaecol Obstet. 1976;14:27–34.CrossRefGoogle ScholarPubMed

Miño, M, Arjona, JE, Cordón, J et al. Success rate and patient satisfaction with the Essure sterilisation in an outpatient setting: A prospective study of 857 women. BJOG. 2007;114:763–6.CrossRefGoogle Scholar

Walter, R, Ghobadi, C, Haymen, E, Xu, S. Hysteroscopic sterilization with Essure. Obstetrics & Gynecology. 2017;129(1):10–19.CrossRefGoogle ScholarPubMed

Vancaillie, TG, Harrington, DC, Anderson, JM. Mechanism of action of the Adiana device: A histologic perspective. Contraception. 2011;84:299–301.CrossRefGoogle ScholarPubMed

Herbst, SJ, Evantash, EG. Clinical performance characteristics of the Adiana system for permanent contraception: The first year of commercial use. Rev Obstet Gynecol. 2010;3:156–62.Google ScholarPubMed

Johns, DA. Advances in hysteroscopic sterilization: Report on 600 patients enrolled in the Adiana EASE pivotal trial. J Minim Invasive Gynecol. 2005;12:39–40.CrossRefGoogle Scholar

Westburg, J, Scott, F, Creinin, F. Safety outcomes of female sterilization by salpingectomy and tubal occlusion. Contraception. 2017;95:505–8.Google Scholar

Peterson, HB, DeStefano, F, Rubin, GL et al. Deaths attributable to tubal sterilization in the United States, 1977 to 1981. Am J Obstet Gynecol. 1983; 146:131–6.CrossRefGoogle ScholarPubMed

Van Seeters, JAH, Chua, SJ, Mol, BWJ, Koks, CAM. Tubal anastomosis after previous sterilization: A systematic review. Human Reproduction Update. 2017;1–13.CrossRefGoogle Scholar

Whittemore, AS, Wu, ML, Paffenbarger, RS et al. Personal and environmental characteristics related to epithelial ovarian cancer-exposures to talcum powder, tobacco, alcohol and coffee. Am J Epidemiol. 1988;128:1228.CrossRefGoogle ScholarPubMed

Cibula, D, Widschwendter, M, Majek, O et al. Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Hum Reprod Update. 2011;17:55–67.CrossRefGoogle ScholarPubMed

International Consortium for Emergency Contraception. In depth country information. www.cecinfo.org/country-by-country-information/in-depth.Google Scholar

Cleland, K, Zhu, H, Goldstuck, N, Cheng, L, Trussell, J. The efficacy of intrauterine devices for emergency contraception: A systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000.CrossRefGoogle ScholarPubMed

WHO Model list of essential medicines April 2015. www.who.int/medicines/publications/essentialmedicines/en.s.Google Scholar

Polis, CB, Schaffer, K, Blanchard, K et al. Advance provision of emergency contraception for pregnancy prevention (full review). Cochrane Database Syst Rev. 2007;2:CD005497.Google Scholar

Trussell, J, Ellertson, C, von Hertzen, H et al. Estimating the effectiveness of emergency contraceptive pills. Contraception. 2003;67(4):259–65.CrossRefGoogle ScholarPubMed

Glasier, A, Cameron, ST, Fine, PM et al. Ulipristal acetate versus levonorgestrel for emergency contraception: A randomised non-inferiority trial and meta-analysis. Lancet. 2010;375:555–62.CrossRefGoogle ScholarPubMed

Brache, V, Cochon, L, Deniaud, M, Croxatto, HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: Analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception. 2013;88(5):611–18.CrossRefGoogle ScholarPubMed

Lalitkumar, PG, Lalitkumar, S, Meng, CX et al. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. Hum Reprod. 2007;22(11):3031–7.CrossRefGoogle ScholarPubMed

Berger, C, Boggavarapu, NR, Menezes, J, Lalitkumar, PG, Gemzell-Danielsson, K. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod. 2015;30(4):800–11.CrossRefGoogle Scholar

Zhang, L, Ye, W, Yu, W et al. Physical and mental development of children after levonorgestrel emergency contraception exposure: A follow-up prospective cohort study. Biol Reprod. 2014;91(1):27.CrossRefGoogle ScholarPubMed

Cleland, K, Raymond, E, Trussell, J et al. Ectopic pregnancy and emergency contraceptive pills: A systematic review. Obstet Gynecol. 2010;115:1263–6. https://doi.org/10.1097/AOG.0b013e3181dd22ef.CrossRefGoogle ScholarPubMed

Levy, DP, Jager, M, Kapp, N, Abitbol, JL. Ulipristal acetate for emergency contraception: Postmarketing experience after use by more than 1 million women. Contraception. 2014;89(5):431–3.CrossRefGoogle ScholarPubMed

World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015. www.who.int/publications/i/item/9789241549158.Google Scholar

Faculty of Sexual & Reproductive Healthcare. Emergency contraception (March 2017, amended December 2017). bit.ly/3Y2277Q.Google Scholar

Shen, J, Che, Y, Showell, E, Chen, K, Cheng, L. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019;1(1):CD001324. https://doi.org/10.1002/14651858.CD001324.pub6. PMID: 30661244; PMCID: PMC7055045.Google ScholarPubMed

Glasier, A, Cameron, ST, Blithe, D et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–7.CrossRefGoogle ScholarPubMed

Edelman, AB, Cherala, G, Blue, SW, Erikson, DW, Jensen, JT. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: Single and double dosing. Contraception. 2016;94(1):52–7.CrossRefGoogle ScholarPubMed

Praditpan, P, Hamouie, A, Basaraba, CN et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017;95(5): 464–9. Published Online First: 23 January 2017. https://doi.org/10.1016/j.contraception.2017.01.004. Epub 2017 Jan 23.CrossRefGoogle ScholarPubMed

Cameron, ST, Glasier, A, McDaid, L et al. Use of effective contraception following provision of the progestogen-only pill for women presenting to community pharmacies for emergency contraception (Bridge-It): A pragmatic cluster-randomised crossover trial. Lancet. 2020;396(10262):1585–94. https://doi.org/10.1016/S0140-6736(20)31785-2. PMID: 33189179; PMCID: PMC7661838.CrossRefGoogle ScholarPubMed

Stanford, JB, Mikolajczyk, RT. Mechanisms of action of intrauterine devices: Update and estimation of postfertilization effects. Am J Obstet Gynecol. 2002;187:1699–1708.CrossRefGoogle ScholarPubMed

Moreau, C, Bouyer, J, Goulard, H, Bajos, N. The remaining barriers to the use of emergency contraception: Perception of pregnancy risk by women undergoing induced abortions. Contraception. 2005;71:202–7.CrossRefGoogle Scholar

Massai, MR, Forcelledo, ML, Brache, V et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study. Hum Reprod. 2007;22:434–9.CrossRefGoogle ScholarPubMed

Cameron, ST, Critchley, HOD, Buckley, CH, Kelly, RW, Baird, DT. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertility and Sterility. 1997;67:1046–53.CrossRefGoogle ScholarPubMed

Willetts, SJ, MacDougall, M, Cameron, ST. A survey regarding acceptability of oral emergency contraception according to the posited mechanism of action. Contraception. 2017;96(2):81–8. https://doi.org/10.1016/j.contraception.2017.03.012. Epub 2017 Apr 3. PMID: 28385554.CrossRefGoogle Scholar

Xiao, B, von Hertzen, H, Zhao, H, Piaggio, G. Menstrual induction with mifepristone and misoprostol. Contraception. 2003;68(6):489–94.CrossRefGoogle ScholarPubMed

Bitzer, J, Simon, JA. Current issues and available options in combined hormonal contraception. Contraception. 2011;84(4):342–56.CrossRefGoogle ScholarPubMed

Sabatini, R, Cagiano, R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74(3):220–3.CrossRefGoogle ScholarPubMed

Yu, Q, Huang, Z, Ren, M et al. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: A multicenter, open-label, uncontrolled Phase III study. Int J Womens Health. 2018;10:257–66.CrossRefGoogle Scholar

Van Vliet, HA, Grimes, DA, Lopez, LM, Schulz, KF, Helmerhorst, FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;11:CD003553.Google Scholar

Lawrie, TA, Helmerhorst, FM, Maitra, NK et al. Types of progestogens in combined oral contraception: Effectiveness and side-effects. Cochrane Database Syst Rev. 2011;5:CD004861.Google Scholar

Lopez, LM, Grimes, DA, Gallo, MF, Stockton, LL, Schulz, KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;4:CD003552.Google Scholar

Palacios, S, Colli, E, Regidor, PA. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet. 2019;300(6):1805–12.CrossRefGoogle ScholarPubMed

ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16(7):1527–35.Google Scholar

Diedrich, JT, Zhao, Q, Madden, T, Secura, GM, Peipert, JF. Three-year continuation of reversible contraception. Am J Obstet Gynecol. 2015;213(5):662.e1–8.CrossRefGoogle ScholarPubMed

Fruzzetti, F, Paoletti, AM, Fidecicchi, T et al. Contraception with estradiol valerate and dienogest: Adherence to the method. Open Access J Contracept. 2019;10:1–6.CrossRefGoogle ScholarPubMed

Zigler, RE, McNicholas, C. Unscheduled vaginal bleeding with progestin-only contraceptive use. Am J Obstet Gynecol. 2017;216(5):443–50.CrossRefGoogle ScholarPubMed

Vincent, AJ, Zhang, J, Ostör, A et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: A role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding? Hum Reprod. 2002;17(5):1189–98.CrossRefGoogle ScholarPubMed

Hickey, M, Crewe, J, Mahoney, LA et al. Mechanisms of irregular bleeding with hormone therapy: The role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab. 2006;91(8):3189–98.CrossRefGoogle ScholarPubMed

Foran, T. The management of irregular bleeding in women using contraception. Aust Fam Physician. 2017;46(10):717–20.Google ScholarPubMed

Duijkers, I, Klipping, C, Heger-Mahn, D et al. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing. Eur J Contracept Reprod Health Care. 2018;23(4):245–54.CrossRefGoogle ScholarPubMed

Virro, JJ, Besinque, K, Carney, CE et al. Long-lasting, patient-controlled, procedure-free contraception: A review of Annovera with a pharmacist perspective. Pharmacy (Basel). 2020;8(3):156–61.Google ScholarPubMed

Kaneshiro, B, Edelman, A, Carlson, NE et al. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012;85(4):351–8.CrossRefGoogle ScholarPubMed

Madden, T, Proehl, S, Allsworth, JE, Secura, GM, Peipert, JF. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: A randomized controlled trial. Am J Obstet Gynecol. 2012;206(2):129.e1–8.CrossRefGoogle ScholarPubMed

Weisberg, E, Hickey, M, Palmer, D et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod. 2006;21(1):295–302.CrossRefGoogle ScholarPubMed

Sørdal, T, Inki, P, Draeby, J, O’Flynn, M, Schmelter, T. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: A randomized controlled trial. Obstet Gynecol. 2013;121(5):934–41.CrossRefGoogle ScholarPubMed

Papaikonomou, K, Kopp Kallner, H, Söderdahl, F, Gemzell-Danielsson, K. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control: A randomized controlled trial. Hum Reprod. 2018;33(11):2002–9.CrossRefGoogle ScholarPubMed

Cohen, MA, Simmons, KB, Edelman, AB, Jensen, JT. Tamoxifen for the prevention of unscheduled bleeding in new users of the levonorgestrel 52-mg intrauterine system: A randomized controlled trial. Contraception. 2019;100(5):391–6.CrossRefGoogle ScholarPubMed

Simmons, KB, Edelman, AB, Fu, R, Jensen, JT. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: A randomized controlled trial. Contraception. 2017;95(2):198–204.CrossRefGoogle ScholarPubMed

Zigler, RE, Madden, T, Ashby, C, Wan, L, McNicholas, C. Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: A randomized controlled trial. Obstet Gynecol. 2018;132(4):888–94.CrossRefGoogle ScholarPubMed

Skovlund, CW, Mørch, LS, Kessing, LV, Lidegaard, Ø. Association of hormonal contraception with depression. JAMA Psychiatry. 2016:73:1154–62.CrossRefGoogle ScholarPubMed

Keyes, KM, Cheslack-Postava, K, Westhoff, C et al. Association of hormonal contraceptive use with reduced levels of depressive symptoms: A national study of sexually active women in the United States. Am J Epidemiol. 2013;178:1378–88.CrossRefGoogle ScholarPubMed

Wien, AB, Foldemo, A, Josefsson, A, Lindberg, M. Use of hormonal contraceptives in relation to antidepressant therapy: A nationwide population-based study. Eur J Contracept Reprod Health Care. 2010;15:41–7.Google Scholar

Lindberg, M, Foldemo, A, Josefsson, A, Wiréhn, AB. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: A nationwide population-based study with age-specific analyses. Eur J Contracept Reprod Health Care. 2012;17:106–18.CrossRefGoogle ScholarPubMed

Young, EA, Kornstein, SG, Harvey, AT et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology. 2007;32:843–53.CrossRefGoogle ScholarPubMed

Pearlstein, TB, Bachmann, GA, Zacur, HA, Yonkers, KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–21.CrossRefGoogle ScholarPubMed

Oinonen, KA, Mazmanian, D. To what extent do oral contraceptives influence mood and affect? J Affect Disord. 2002;70:229–40.CrossRefGoogle ScholarPubMed

Rapkin, AJ, Morgan, M, Sogliano, C et al. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril. 2006;85:1371–8.CrossRefGoogle Scholar

Pfaus, JG. Pathways of sexual desire. J Sex Med. 2009;6:1506–33.CrossRefGoogle ScholarPubMed

Brotto, LA, Bitzer, J, Laan, E, Leiblum, S, Luria, M. Women’s sexual desire and arousal disorders. J Sex Med. 2010;7:586–614.CrossRefGoogle ScholarPubMed

Dei, M, Verni, A, Bigozzi, L, Bruni, V. Sex steroids and libido. Eur J Contracept Reprod Health Care. 1997;2(4):253–8.CrossRefGoogle ScholarPubMed

Davis, A, Castano, P. Oral contraceptives and libido in women. Annu Rev Sex Res. 2004;15:297–320.Google ScholarPubMed

Graham, CA, Ramos, R, Bancroft, J, Maglaya, C, Farley, TM. The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception. 1995;52:363–9.CrossRefGoogle ScholarPubMed

Cullberg, J, Gelli, MG, Jonsson, CO. Mental and sexual adjustment before and after six months’ use of an oral contraceptive. Acta Psychiatrica Scandinavica. 1969;45: 259–76.CrossRefGoogle ScholarPubMed

Graham, C, Sherwin, B. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology. 1993;18(4):273–81.CrossRefGoogle ScholarPubMed

Plewig, G, Cunliffe, W, Binder, N, Höschen, K. Efficacy of an oral contraceptive containing ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg (EE/CMA; Belara®) in moderate acne resolution: A randomised, double-blind, placebo-controlled phase III trial. Contraception. 2008:123–30.CrossRefGoogle Scholar

Erkkola, R, Hirvonen, E, Luikku, J et al. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstetricia et Gynecologica Scandinavica. 1990;69:61–5.CrossRefGoogle ScholarPubMed

Endrikat, J, Hite, R, Bannemerschult, R, Gerlinger, C, Schmidt, W. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. Contraception. 2001;64(1):3–10.CrossRefGoogle ScholarPubMed

Worret, I, Arp, W, Zahradnik, H, Andreas, J, Binder, N. Acne resolution rates: Results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203(1):38–44.CrossRefGoogle ScholarPubMed

Sanders, S, Graham, C, Bass, J, Bancroft, J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64(1):51–8.CrossRefGoogle ScholarPubMed

Aznar-Ramos, R, Ginger-Velazquez, J, Lara-Ricalde, R, Martinez-Manautou, J. Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol. 1969;105(7):1144–9.CrossRefGoogle ScholarPubMed

Martin-Loeches, M, Orti, R, Monfort, M, Ortega, E, Rius, J. A comparative analysis of the modification of sexual desire of users of oral hormonal contraceptives and intrauterine contraceptive devices. Eur J Contracept Reprod Health Care. 2003;8(3):129–34.CrossRefGoogle ScholarPubMed

Schaffir, J. Hormonal contraception and sexual desire: A critical review. J Sex Marital Ther. 2006;32(4):305–14.CrossRefGoogle ScholarPubMed

Pohl, O, Osterloh, I, Lecomte, V, Gotteland, JP. Changes in gastric pH and in pharmacokinetics of ulipristal acetate: A drug–drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26–33.CrossRefGoogle ScholarPubMed

Simmons, KB, Kumar, N, Plagianos, M et al. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: A randomized, crossover drug–drug interaction study. Contraception. 2018;97(3):270–6.CrossRefGoogle ScholarPubMed

Reimers, A, Brodtkorb, E, Sabers, A. Interactions between hormonal contraception and antiepileptic drugs: Clinical and mechanistic considerations. Seizure. 2015;28:66–70.CrossRefGoogle ScholarPubMed

Lee, CR. Drug interactions and hormonal contraception. Trends in Urology Gynaecology & Sexual Health. 2009:23–6.CrossRefGoogle Scholar

US Food and Drug Administration. Drug development and drug interactions: Table of substrates, inhibitors and inducers. http://bit.ly/3JpjGL7.Google Scholar

Reddy, DS. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol. 2010;3(2):183–92.CrossRefGoogle ScholarPubMed

Herzog, AG, Mandle, HB, Cahill, KE, Fowler, KM, Hauser, WA. Differential impact of contraceptive methods on seizures varies by antiepileptic drug category: Findings of the Epilepsy Birth Control Registry. Epilepsy Behav. 2016;60:112–17.CrossRefGoogle ScholarPubMed

Berry-Bibee, EN, Kim, MJ, Simmons, KB et al. Drug interactions between hormonal contraceptives and psychotropic drugs: A systematic review. Contraception. 2016;94(6):650–67.CrossRefGoogle ScholarPubMed

Schoretsanitis, G, Kane, JM, de Leon, J. Adding oral contraceptives to clozapine may require halving the clozapine dose: A new case and a literature review. J Clin Psychopharmacol. 2020;40(3):308–10.CrossRefGoogle Scholar

Ti, A, Stone, RH, Whiteman, M, Curtis, KM. Safety and effectiveness of hormonal contraception for women who use opioids: A systematic review. Contraception. 2019;100(6):480–3.CrossRefGoogle ScholarPubMed

Qian, Y, Gurley, BJ, Markowitz, JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol. 2019;39(5):462–71.CrossRefGoogle ScholarPubMed

Robertson, P, DeCory, HH, Madan, A, Parkinson, A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos. 2000;28(6):664–71.Google ScholarPubMed

Robertson, P, Jr, Hellriegel, ET, Arora, S, Nelson, M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther. 2002;71(1):46–56.CrossRefGoogle ScholarPubMed

Simmons, KB, Haddad, LB, Nanda, K, Curtis, KM. Drug interactions between rifamycin antibiotics and hormonal contraception: A systematic review. BJOG. 2018;125(7):804–11.CrossRefGoogle ScholarPubMed

Simmons, KB, Haddad, LB, Nanda, K, Curtis, KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: A systematic review. Am J Obstet Gynecol. 2018;218(1):88–97.e14.CrossRefGoogle ScholarPubMed

Dogterom, P, van den Heuvel, MW, Thomsen, T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet. 2005;44(4):429–38.CrossRefGoogle ScholarPubMed

Hendrix, CW, Jackson, KA, Whitmore, E et al. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004;75(5):464–75.CrossRefGoogle ScholarPubMed

Bailard, N, Rebello, E. Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. Br J Clin Pharmacol. 2018;84(3):602–3.CrossRefGoogle ScholarPubMed

Van Giersbergen, PL, Halabi, A, Dingemanse, J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther. 2006;44(3):113–18.Google ScholarPubMed

Zhang, N, Shon, J, Kim, MJ et al. Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018;11(3):251–60.CrossRefGoogle ScholarPubMed

Verhoeven, CH, van den Heuvel, MW, Mulders, TM, Dieben, TO. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. Contraception. 2004;69(2):129–32.Google ScholarPubMed

Ezuruike, U, Humphries, H, Dickins, M et al. Risk-benefit assessment of ethinylestradiol using a physiologically based pharmacokinetic modeling approach. Clin Pharmacol Ther. 2018;104(6):1229–39.CrossRefGoogle ScholarPubMed

Catalano, PM, Blank, H. Griseofulvin–oral contraceptive interaction. Arch Dermatol. 1985;121(11):1381–7.CrossRefGoogle ScholarPubMed

Berry-Bibee, EN, Kim, MJ, Tepper, NK, Riley, HE, Curtis, KM. Co-administration of St. John’s wort and hormonal contraceptives: A systematic review. Contraception. 2016;94(6):668–77.CrossRefGoogle ScholarPubMed

Edelman, AB, Jensen, JT, McCrimmon, S et al. Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study. Contraception. 2018;98(6):463–6.CrossRefGoogle ScholarPubMed

Cameron, ST, Berger, C, Michie, L, Klipping, C, Gemzell-Danielsson, K. The effects on ovarian activity of ulipristal acetate when ‘quickstarting’ a combined oral contraceptive pill: A prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod. 2015;30(7):1566–72.CrossRefGoogle Scholar

Dominick, SA, McLean, MR, Whitcomb, BW et al. Contraceptive practices among female cancer survivors of reproductive age. Obstet Gynecol. 2015;126(3):498–507.CrossRefGoogle ScholarPubMed

Hadnott, TN, Stark, SS, Medica, A et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019;111(4):763–71.CrossRefGoogle ScholarPubMed

Plu-Bureau, G, Maitrot-Mantelet, L, Hugon-Rodin, J, Canonico, M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27(1):25–34.CrossRefGoogle ScholarPubMed

Chelmow, D, Pearlman, MD, Young, A et al. Executive summary of the Early-Onset BC Evidence Review Conference. Obstet Gynecol. 2020;135(6):1457–78.CrossRefGoogle Scholar

Thavendiranathan, P, Nolan, MT. An emerging epidemic: Cancer and heart failure. Clin Sci (Lond). 2017;131(2):113–21.CrossRefGoogle ScholarPubMed

Taylor, C, Correa, C, Duane, FK et al. Estimating the risks of BC radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9.CrossRefGoogle Scholar

Heer, E, Harper, A, Escandor, N et al. Global burden and trends in premenopausal and postmenopausal BC: A population-based study. Lancet Glob Health. 2020;8(8):e1027–37.CrossRefGoogle Scholar

Parisi, F, Razeti, MG, Blondeaux, E et al. Current state of the art in the adjuvant systemic treatment of premenopausal patients with early BC. Clin Med Insights Oncol. 2020;14:1179554920931816.CrossRefGoogle Scholar

Sofiyeva, N, Siepmann, T, Barlinn, K, Seli, E, Ata, B. Gonadotropin-releasing hormone analogs for gonadal protection during gonadotoxic chemotherapy: A systematic review and meta-analysis. Reprod Sci. 2019;26(7):939–53.CrossRefGoogle ScholarPubMed

Gompel, A, Ramirez, I, Bitzer, J, European Society of Contraception Expert Group on Hormonal Contraception. Contraception in cancer survivors: An expert review Part I. Breast and gynaecological cancers.Eur J Contracept Reprod Health Care. 2019;24(3):167–74.CrossRefGoogle ScholarPubMed

Valachis, A, Tsali, L, Pesce, LL et al. Safety of pregnancy after primary breast carcinoma in young women: A meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv. 2010;65(12):786–93.CrossRefGoogle ScholarPubMed

World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015. www.who.int/publications/i/item/9789241549158.Google Scholar

Dominick, S, Hickey, M, Chin, J, Su, HI. Levonorgestrel intrauterine system for endometrial protection in women with BC on adjuvant tamoxifen. Cochrane Database Syst Rev. 2015;12:CD007245.CrossRefGoogle Scholar

Kotsopoulos, J, Lubinski, J, Moller, P et al. Timing of oral contraceptive use and the risk of BC in BRCA1 mutation carriers. BC Res Treat. 2014;143(3):579–86.Google Scholar

Endometrial cancer statistics [Internet]. World Cancer Research Fund. 2018. https://bit.ly/3HmkBJI.Google Scholar

Dominguez-Valentin, M, Sampson, JR, Seppälä, TT et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15–25.CrossRefGoogle ScholarPubMed

Baker, J, Obermair, A, Gebski, V, Janda, M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.CrossRefGoogle ScholarPubMed

Koskas, M, Azria, E, Walker, F et al. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res. 2012;32(3):1037–43.Google ScholarPubMed

Bray, F, Ferlay, J, Soerjomataram, I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.Google ScholarPubMed

Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use.: 2.Google Scholar

Rousset-Jablonski, C, Selle, F, Adda-Herzog, E et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: Guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer. 2019;116:35–44.CrossRefGoogle ScholarPubMed

Syngal, S, Brand, RE, Church, JM et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.CrossRefGoogle ScholarPubMed

Cagnacci, A, Ramirez, I, Bitzer, J, Gompel, A. Contraception in cancer survivors: An expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. Eur J Contracept Reprod Health Care. 2019;24(4):299–304.CrossRefGoogle ScholarPubMed

Dashti, SG, Chau, R, Ouakrim, DA et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA. 2015;314(1):61–71.CrossRefGoogle ScholarPubMed

Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. 4th edition. Geneva: World Health Organization, 2010. (WHO Guidelines Approved by the Guidelines Review Committee.) www.ncbi.nlm.nih.gov/books/NBK138639.Google Scholar

Hodgkin lymphoma incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/incidence.Google Scholar

Non-Hodgkin lymphoma incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma/incidence.Google Scholar

Leukaemia (all subtypes combined) incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia/incidence.Google Scholar

Meirow, D, Rabinovici, J, Katz, D et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107(7):1634–41.CrossRefGoogle ScholarPubMed

Bates, JS, Buie, LW, Woodis, CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy. 2011;31(11):1092–1110.CrossRefGoogle ScholarPubMed

Kane, EV, Roman, E, Becker, N et al. Menstrual and reproductive factors, and hormonal contraception use: Associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. Ann Oncol. 2012;23(9):2362–74.CrossRefGoogle Scholar

Iversen, L, Sivasubramaniam, S, Lee, AJ, Fielding, S, Hannaford, PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9.CrossRefGoogle ScholarPubMed

Stapelfeld, C, Dammann, C, Maser, E. Sex-specificity in lung cancer risk. Int J Cancer. 2020;146(9):2376–82.CrossRefGoogle ScholarPubMed

Milosevic, ZC, Nadrljanski, MM, Milovanovic, ZM et al. Breast dynamic contrast enhanced MRI: Fibrocystic changes presenting as a non-mass enhancement mimicking malignancy. Radiol Oncol. 2017;51(2):130–6.CrossRefGoogle ScholarPubMed

Dupont, WD, Page, DL, Parl, FF et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331(1):10–15.CrossRefGoogle ScholarPubMed

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–22.Google Scholar

Vessey, M, Yeates, D. Oral contraceptives and benign breast disease: An update of findings in a large cohort study. Contraception. 2007;76:418–24.CrossRefGoogle Scholar

Rohan, TE, Miller, AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer. 1999;82:191–6.3.0.CO;2-F>CrossRefGoogle ScholarPubMed

Cibula, D, Gompel, A, Mueck, AO et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–50.CrossRefGoogle ScholarPubMed

Li, J, Humphreys, K, Ho, PJ et al. Family history, reproductive, and lifestyle risk factors for fibroadenoma and breast cancer. JNCI Cancer Spectr. 2018;2(3):pky051.CrossRefGoogle ScholarPubMed

Faculty of Sexual & Reproductive Healthcare. UK medical eligibility criteria for contraceptive use (UKMEC). London: Faculty of Sexual & Reproductive Healthcare,2016. www.fsrh.org/standards-and-guidance/documents/ukmec-2016.Google Scholar

Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use (USCDC). 2016. http://bit.ly/3RhFASx.Google Scholar

World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015.Google Scholar

McGurgan, P, Taylor, LJ, Duffy, SR et al. Are endometrial polyps from pre-menopausal women similar to post-menopausal women? An immunohistochemical comparison of endometrial polyps from pre- and post-menopausal women. Maturitas. 2006;54:277–84.CrossRefGoogle ScholarPubMed

Cohen, I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–66.CrossRefGoogle ScholarPubMed

Wada-HiraikeE, O, Osuga, Y, Hiroi, H et al. Sessile polyps and pedunculated polyps respond differently to oral contraceptives. Gynecol Endocrinol. 2011;27(5):351–5.CrossRefGoogle Scholar

Meresman, GF, Auge, L, Baranao, RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril. 2002;77:1141–7.CrossRefGoogle ScholarPubMed

Chowdary, P, Maher, P, Ma, T et al. The role of the Mirena intrauterine device in the management of endometrial polyps: A pilot study. J Minim Invasive Gynecol. 2019;26(7):1297–1302.CrossRefGoogle ScholarPubMed

Vannuccini, S, Luisi, S, Tosti, C et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.CrossRefGoogle ScholarPubMed

Fedele, L, Portuese, A, Bianchi, S et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68:426–9.CrossRefGoogle ScholarPubMed

Critchley, HOD, Wang, H, Kelly, RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998;13:1210–17.CrossRefGoogle ScholarPubMed

Sheng, J, Zhang, WY, Zhang, JP et al. The LNG-IUS study on adenomyosis: A 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79:189–93.CrossRefGoogle Scholar

Ozdegirmenci, O, Kayikcioglu, F, Akgul, MA et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95:497–502.CrossRefGoogle ScholarPubMed

Shaaban, OM, Ali, MK, Sabra, AM et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: A randomized clinical trial. Contraception. 2015;92(4):301–7.CrossRefGoogle ScholarPubMed

Grandi, G, De Fata, R, Varliero, F et al. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning. Gynecol Endocrinol. 2020;36(12):1086–9.CrossRefGoogle Scholar

Ross, RK, Pike, MC, Vessey, MP et al. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. BMJ. 1988;293:359–62.Google Scholar

Lethaby, AE, Cooke, I, Rees, M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006:CD002126.CrossRefGoogle Scholar

Starczewski, A, Iwanicki, M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol. 2000;71(9):1221–5.Google ScholarPubMed

Soysal, S, Soysal, ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: A prospective controlled trial. Gynecol Obstet Invest. 2005;59(1):29–35.CrossRefGoogle ScholarPubMed

Sayed, GH, Zakherak, MS, El-Nashar, SA et al. A randomized clinical trial of levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. International Journal of Gynecology and Obstetrics. 2011;112:126–30.CrossRefGoogle Scholar

Zapata, LB, Whiteman, MK, Tepper, NK et al. Intrauterine device use among women with uterine fibroids: A systematic review. Contraception. 2010;82:41–55.CrossRefGoogle ScholarPubMed

Marret, H, Fritel, X, Ouldamer, L et al. Therapeutic management of uterine fibroid tumors: Updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165:156–64.CrossRefGoogle ScholarPubMed

Sletten, ET, Arnes, M, Vereide, AB et al. Low-dose LNG-IUS as therapy for endometrial hyperplasia: A prospective cohort pilot study. Anticancer Res. 2018;38(5):2883–9.Google ScholarPubMed

Whiteman, MK, Zapata, LB, Tepper, NK et al. Use of contraceptive methods among women with endometrial hyperplasia: A systematic review. Contraception. 2010;82(1):56–63.CrossRefGoogle ScholarPubMed

Coburn, SB, Bray, F, Sherman, ME et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–60.CrossRefGoogle ScholarPubMed

Grimes, DA, Jones, LB, Lopez, LM et al. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 9:CD006134.Google Scholar

Holt, VL, Daling, JR, McKnight, B et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol. 1992;79:529–33.Google Scholar

Grandi, G, Barra, F, Ferrero, S et al. Hormonal contraception in women with endometriosis: Asystematic review. Eur J Contracept Reprod Health Care. 2019;24(1):61–70.CrossRefGoogle Scholar

Grandi, G, Toss, A, Cortesi, L et al. The association between endometriomas and ovarian cancer: Preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int. 2015:751571.CrossRefGoogle Scholar

De Melo, AS, Dos Reis, RM, Ferriani, RA et al. Hormonal contraception in women with polycystic ovary syndrome: Choices, challenges, and noncontraceptive benefits. Open Access J Contraception. 2017;8:13–23.CrossRefGoogle ScholarPubMed

Charitidou, C, Farmakiotis, D, Zournatzi, V et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008:196(2):958–65.CrossRefGoogle ScholarPubMed

Bhattacharya, SM, Jha, A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053–9.CrossRefGoogle ScholarPubMed

Legro, RS, Arslanian, SA, Ehrmann, DA et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.CrossRefGoogle ScholarPubMed

Fauser, BC, Tarlatzis, BC, Rebar, RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM–Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.CrossRefGoogle ScholarPubMed

Conway, G, Dewailly, D, Diamanti-Kandarakis, E et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1–29.CrossRefGoogle ScholarPubMed

Li, J, Ren, J, Sun, W. A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2017;210:13–21.CrossRefGoogle ScholarPubMed

Del Savio, MC, De Fata, R, Facchinetti, F et al. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: A new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–94.Google Scholar

Yusuf, S, Hawken, S, Ounpuu, S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364(9438):937–52.CrossRefGoogle ScholarPubMed

O’Donnell, MJ, Xavier, D, Liu, L et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet. 2010;376(9735):112–23.Google ScholarPubMed

Hannaford, PC, Croft, PR, Kay, CR. Oral contraception and stroke: Evidence from the Royal College of General Practitioners’ Oral Contraception Study. Stroke. 1994;25:935–42.CrossRefGoogle ScholarPubMed

Poulter, NR for the WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. Lancet. 1996;348:498–505.Google Scholar

Weill, A, Dalichampt, M, Raguideau, F et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: Cohort study. BMJ. 2016;353:i2002.CrossRefGoogle ScholarPubMed

Roach, RE, Helmerhorst, FM, Lijfering, WM et al. Combined oral contraceptives: The risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;8:CD011054.Google Scholar

Lidegaard, Ø, Kreiner, S. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception. 2002;65:197–205.CrossRefGoogle ScholarPubMed

Lidegaard, Ø, Løkkegaard, E, Jensen, A, Skovlund, CW, Keiding, N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257–66.CrossRefGoogle ScholarPubMed

Dinger, J, Mohner, S, Heinemann, K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception. 2016;93:378–85.CrossRefGoogle ScholarPubMed

Dinger, J, Mohner, S, Heinemann, K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Front Women’s Health. 2020; 5:1–8.CrossRefGoogle Scholar